Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | NOXO1 | Q8NFA2 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | PLG | P00747 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | LY6K | Q17RY6 | 1/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14315660 | 0.89 | FOLH1 (0.55) | FOLH1HSP90AB1NOXO1GBA1PRSS1 | |
| SCHEMBL10191057 | 0.88 | FOLH1 (0.55) | FOLH1HSP90AB1NOXO1GBA1PRSS1 | |
| SCHEMBL21008402 | 0.87 | FOLH1 (0.55) | FOLH1HSP90AB1NOXO1GBA1PRSS1 | |
| SCHEMBL19326743 | 0.87 | FOLH1 (0.58) | FOLH1HSP90AB1NOXO1GBA1PRSS1 | |
| SCHEMBL13528559 | 0.85 | PKM (0.60) | FOLH1HSP90AB1NOXO1GBA1PRSS1 | |
| SCHEMBL5806320 | 0.85 | FOLH1 (0.52) | FOLH1HSP90AB1NOXO1PRSS1PRSS2 | |
| SCHEMBL20519815 | 0.84 | FOLH1 (0.57) | FOLH1HSP90AB1NOXO1PRSS1PRSS2 | |
| SCHEMBL20520127 | 0.83 | PRSS1 (0.58) | FOLH1HSP90AB1NOXO1PRSS1PRSS2 | |
| SCHEMBL20519966 | 0.83 | PRSS1 (0.58) | FOLH1HSP90AB1NOXO1PRSS1PRSS2 | |
| SCHEMBL13986332 | 0.83 | L3MBTL3 (0.52) | FOLH1HSP90AB1NOXO1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2008029281-A2 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | RNGTT, ADAR, ALKBH1 | FOLH1 1109/4885HSP90AB1 3267/4885NOXO1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.